Biologically Active Small Molecules

PGE1 is not a major naturally occurring prostaglandin, but it is widely administered clinically for several indications including peripheral occlusive vascular disease, erectile dysfunction, and in neonatal cardiology. The metabolism of PGE1 is

PGE1 is not a major naturally occurring prostaglandin, but it is widely administered clinically for several indications including peripheral occlusive vascular disease, erectile dysfunction, and in neonatal cardiology. The metabolism of PGE1 is

PGE1 is not a major naturally occurring prostaglandin, but it is widely administered clinically for several indications including peripheral occlusive vascular disease, erectile dysfunction, and in neonatal cardiology. The metabolism of PGE1 is

TXB2 is released in substantial quantities from aggregating platelets and metabolized during circulation to 11-dehydro TXB2 and 2,3-dinor TXB2.{1410} In rats and rabbits, 2,3-dinor TXB1 has been identified as another urinary metabolite of TXB2.

TXB2 is released in substantial quantities from aggregating platelets and metabolized during circulation to 11-dehydro TXB2 and 2,3-dinor TXB2.{1410} In rats and rabbits, 2,3-dinor TXB1 has been identified as another urinary metabolite of TXB2.

TXB2 is released in substantial quantities from aggregating platelets and metabolized during circulation to 11-dehydro TXB2 and 2,3-dinor TXB2.{1410} In rats and rabbits, 2,3-dinor TXB1 has been identified as another urinary metabolite of TXB2.

An endogenous CB neurotransmitter that binds to both CB1 and CB2 receptors.

An endogenous CB neurotransmitter that binds to both CB1 and CB2 receptors.

An endogenous CB neurotransmitter that binds to both CB1 and CB2 receptors.

An intertnal standard for the quantification of 2,3-dinor TXB2 by GC- or LC-MS.

An intertnal standard for the quantification of 2,3-dinor TXB2 by GC- or LC-MS.

An intertnal standard for the quantification of 2,3-dinor TXB2 by GC- or LC-MS.